Key facts
- This page summarizes Ashley Hall's Form 4 filing for Reneo Pharmaceuticals, Inc. (OKUR).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 29 Aug 2023, 17:04.
Ashley Hall - 28 Aug 2023 Form 4 Insider Report for Reneo Pharmaceuticals, Inc. (OKUR)
- Reporting relationship
- Chief Development Officer
- Issuer ticker
- OKUR
- Reported as of
- 28 Aug 2023
- Net transaction value
- -$69,933
- SEC form
- 4
- Accepted by SEC
- 29 Aug 2023, 17:04:03 UTC
- Prior SEC filing
- 13 Dec 2022
- Next SEC filing
- 20 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer P. Lam, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ashley Hall filed Form 4 for Reneo Pharmaceuticals, Inc. (OKUR) on 29 Aug 2023.
Change
- Previous filing in this sequence was filed on 13 Dec 2022.
- Current net transaction value: -$69,933.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RPHM
transaction
Common Stock
Options Exercise
- Transaction value
- $28,125
- Shares
- +15,625
- Change %
- +39%
- Price
- $1.80
- Shares after
- 55,225
- Date
- 28 Aug 2023
- Ownership
- Direct
- Footnotes
- F1
RPHM
transaction
Common Stock
Sale
- Transaction value
- $98,058
- Shares
- -15,625
- Change %
- -28%
- Price
- $6.28
- Shares after
- 39,600
- Date
- 28 Aug 2023
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RPHM
transaction
Derivative
Stock option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -15,625
- Change %
- -12%
- Price
- $0.000000
- Shares after
- 109,375
- Date
- 28 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,625
- Exercise price
- $1.80
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Includes 4,000 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on June 8, 2023.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.24 to $6.44, inclusive. The reporting person undertakes to provide any security holder of Reneo Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
Footnote F3
The shares vest in a series of 16 equal quarterly installments measured from December 9, 2022 subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date.